2022 QSP Virtual Symposium

Dr. Bozic is also an affiliate faculty member in the Herbold Computational Biology Program at the Fred Hutchinson Cancer Research Center in Seattle. She received her BSc and MA degrees in mathematics from the University of Belgrade, Serbia, and her PhD in mathematics from Harvard University. Her group at the University of Washington develops mathematical and computational models to study the evolutionary dynamics of cancer and its response to therapy. She is the recipient of the NSF CAREER Award and the Johnson & Johnson WiSTEM2D Scholars Award.

Dr. Ideker directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives. Trey received BS and MEng degrees in Computer Science from MIT and his PhD in Genome Sciences from the University of Washington. Trey is a pioneer in genomic, transcriptomic, and proteomic analysis and in the theory and practice of Systems Biology. He founded and continues to develop the widely used Cytoscape network analysis platform (>30,000 citations). Trey is on the Board of Scientific Advisors to the National Cancer Institute. Trey is an AAAS & AIMBE Fellow, and is a Web of Science Highly Cited Researcher (top 1% by citations).

Dr. Kholodenko is a member of the Royal Irish Academy, and Adjunct Professor of Pharmacology, Yale University, New Haven, USA. He received a PhD in Biophysics from the Moscow Institute of Physics and Technology and a Dr.Sc. from Moscow State University.  He is a pioneer in the field of systems biology and provides mechanistic insights into cell signalling networks and their characteristic behaviours.

Matthew Lazzara received a BS in Chemical Engineering from the University of Florida and a PhD in Chemical Engineering from the Massachusetts Institute of Technology and remained at MIT for postdoctoral studies in the lab of Douglas Lauffenburger and was the recipient of an NIH Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship. The Lazzara Lab research employs a combination of experimental and computational methods to study problems in cell signaling. Current projects focus on the rational (model-driven) identification of combination therapies for cancer and on fundamental studies of the spatiotemporal regulation of cell signaling by phosphatases and receptor trafficking. 

Dr. Nekka, received a PhD in mathematics in the field of fractal analysis, and has evolved her research into the areas of Pharmacometrics and Quantitative Systems Pharmacology (QSP).  Her projects span a whole range of therapeutic areas, involving fundamental aspects for methodologies development, their applications, and their translation to the end users at the academic, industrial and regulatory levels. She is an active mentor of a new generation of highly qualified personnel, trained between mathematics and pharmaceutical sciences. 

Dr. Randles received her BS degree from Duke University and both her MS (Computer Sciences ) and PhD (Applied Physics) degrees from Harvard University. Her research in biomedical simulation and high-performance computing focuses on the development of new computational tools that we use to provide insight into the localization and development of human diseases ranging from atherosclerosis to cancer. Amongst her many awards, she has received the NSF CAREER award.  

Dr. Riggs received his BS degree in Pharmacy and PhD in Pharmaceutical Science from the University of Connecticut School of Pharmacy. Following a post-doctoral fellowship at GloboMax LLC (now ICON Development Solutions), Matthew worked for 5 years at Pfizer Global Research and Development and was an Associate Director and Clinical Pharmacology prior to joining MetrumRG as a Team Leader. At MetrumRG he leads research efforts to develop and integrate translational, quantitative, and systems pharmacology within model-driven therapeutics development. He is an ISoP Fellow and was the co-recipient of 2019 ISoP Innovation Award.

Dr. Sorger received his PhD from Trinity College in Cambridge; trained as a postdoctoral fellow at UCSF; and served as a Professor of Biology and Biological Engineering at MIT. Peter’s research uses mathematical and experimental approaches to study signal transduction networks controlling cell proliferation and death, dysregulation of these networks in cancer and inflammatory diseases and mechanisms of action of therapeutic drugs targeting signaling proteins.  The Sorger group also develops open-source software for analyzing biological networks and drug mechanism of action and it participates in multiple collaborative programs working to improve data access and reproducibility.